Efficacy and Safety of Probiotics in Neonatal Hyperbilirubinemia
NCT ID: NCT03266913
Last Updated: 2017-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
126 participants
INTERVENTIONAL
2017-08-01
2017-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Phototherapy With and Without Probiotics
NCT06173856
The Effectiveness of Probiotics in Neonatal Jaundice
NCT06449508
The Effect of Probiotics Added to the Mother's Diet on Preterm Babies
NCT06118801
Role of Probiotics for Prevention of NEC in Preterm VLBW Infants
NCT02650869
Heat Killed Probiotics in the Prevention of Necrotizing Enterocolitis
NCT02796703
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic
Routine phototherapy plus probiotic oral drops at the dose of 10 drops daily
Probiotic
Probiotics drop
No probiotic
Routine phototherapy
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic
Probiotics drop
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having jaundice
* Gestational age between 35-42 weeks
Exclusion Criteria
* Gestational age out of the range of 35-42 weeks
* Infants whose parents refused to cooperate
* Patients with sepsis and other comorbid conditions
2 Days
28 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hormozgan University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hamidreza Mahboobi
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rakhshaneh Goodarzi, M.D
Role: PRINCIPAL_INVESTIGATOR
Hormozgan University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children hospital
Bandar Abbas, Hormozgan, Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4889
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.